Iambic
Iambic Therapeutics is a clinical-stage biotech using proprietary AI platforms (Enchant and NeuralPLexer) integrated with an automated wet lab to discover and develop small molecule therapeutics, partnering with large pharmaceutical companies such as Takeda, Bayer, and Jazz Pharmaceuticals.
- Company typePrivate
- Founded2020
- HeadquartersSan Diego, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Iambic does
Iambic Therapeutics is a clinical-stage, privately held biotechnology company headquartered in San Diego, California, with additional offices in Boston and Cambridge, UK, founded in 2019/2020 by Tom Miller, PhD (CEO) and Fred Manby, PhD (CTO). The company is developing an integrated AI-driven drug discovery platform that combines two proprietary AI technologies — Enchant, a multi-modal transformer that predicts clinical outcomes from early-stage molecular data, and NeuralPLexer, a generative AI model for protein-ligand complex structure prediction — with an automated high-throughput wet lab that generates proprietary biological data on a weekly cadence. Iambic's internal pipeline includes IAM1363, a selective brain-penetrant HER2 inhibitor that entered Phase 1 in March 2024 (approximately 2 years from discovery, versus a 6-year industry benchmark), as well as preclinical candidates IAM-K1 (KIF18A inhibitor) and IAM-C1 (CDK2/4 inhibitor). The company has been recognized on the CNBC Disruptor 50 list in 2025 and 2026.
Iambic operates a B2B enterprise model, partnering with large pharmaceutical companies through multi-year collaboration agreements rather than selling discrete products. Revenue is generated through upfront payments, research funding, technology access fees, milestone payments, and royalties on net sales of any partnered products. Named partners include Takeda (a February 2026 collaboration potentially exceeding $1.7B in milestone and royalty value for oncology and GI/inflammation), Bayer (a June 2026 sourcing collaboration for small molecule discovery), Jazz Pharmaceuticals (HER2 combination therapy in HER2-positive breast cancer), Revolution Medicines (technology collaboration using NeuralPLexer), Lundbeck (migraine drug discovery), and Lambda AI (next-generation AI infrastructure). The company is venture-backed, with over $350M raised from institutional investors including Abingworth, Sequoia Capital, Mubadala Capital, Exor Ventures, Qatar Investment Authority, Alexandria Venture Investments, the Ireland Strategic Investment Fund, and NVIDIA, and employs more than 140 people across its three sites.
Iambic firmographics
Firmographics- Name
- Iambic
- Legal name
- Iambic Therapeutics, Inc.
- Website
- https://iambic.ai
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Iambic Therapeutics is a clinical-stage biotech using proprietary AI platforms (Enchant and NeuralPLexer) integrated with an automated wet lab to discover and develop small molecule therapeutics, partnering with large pharmaceutical companies such as Takeda, Bayer, and Jazz Pharmaceuticals.
- Ownership category
- akta.pro rank
Iambic industry classification
Industry- Product category
- AI-driven drug discovery platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Iambic is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Iambic business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Partnership Milestone Payments: Iambic receives upfront payments, research funding, technology access fees, and success-based milestone payments from pharmaceutical partners. The Takeda deal alone could generate over $1.7 billion in potential payments plus royalties on net sales.
- Technology Platform Licensing: Partners gain access to Iambic's AI platforms (Enchant, NeuralPLexer) for drug discovery programs, generating technology access fees and ongoing collaboration payments.
- Royalty Payments: Iambic receives royalties on net sales of any products developed through partnership agreements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Iambic product offering
Product offeringCore offering
Iambic Therapeutics is a clinical-stage biotechnology company that develops an AI-driven drug discovery platform combining proprietary transformer models (Enchant) and protein-ligand structure prediction (NeuralPLexer) with automated high-throughput wet-lab experimentation. The company advances an internal pipeline of differentiated small-molecule oncology candidates (IAM1363, IAM-K1, IAM-C1) and licenses its AI platform to large pharmaceutical companies through multi-year collaboration agreements.
Product overview
Iambic Therapeutics operates as a clinical-stage life science and technology company offering an integrated AI-driven drug discovery platform. The core platform combines two proprietary AI technologies—Enchant (a multi-modal transformer for predicting clinical outcomes) and NeuralPLexer (for protein-ligand structure prediction)—with automated high-throughput experimentation capabilities. The company advances a pipeline of clinical and preclinical assets including IAM1363 (Phase 1 HER2 inhibitor), IAM-K1 (KIF18A inhibitor), and IAM-C1 (CDK2/4 inhibitor), while providing partners access to its industry-leading AI technologies for small molecule drug discovery.
Differentiator
Problem solved
Functional benefit
Products and services
- Enchant A multi-modal transformer AI platform that predicts clinical outcomes from the earliest stages of drug discovery. It integrates physics principles with machine learning to break down data barriers between preclinical and clinical research, and is licensed to pharmaceutical partners for small molecule design.
- NeuralPLexer A generative AI model for protein-ligand complex structure prediction that uses neural network models to predict how drug molecules bind to proteins, enabling rapid identification of differentiated molecules for drug discovery. Licensed to partners such as Takeda and Bayer.
- AI-Driven Drug Discovery Platform An integrated platform combining proprietary AI technologies (Enchant and NeuralPLexer) with automated high-throughput experimentation capabilities that converts novel molecular designs into biological insights weekly, enabling delivery of differentiated clinical candidates at accelerated timelines.
- IAM1363 A highly selective, brain-penetrant Type II HER2 inhibitor for HER2-driven cancers that has demonstrated anti-tumor activity, safety and tolerability in Phase 1b studies. Being evaluated in combination with zanidatamab for HER2-positive breast cancer in collaboration with Jazz Pharmaceuticals.
- IAM-K1 A potential best-in-class, brain-penetrant inhibitor targeting KIF18A for breast cancer, ovarian cancer, and other solid tumors.
- IAM-C1 A potent, highly selective CDK2/4 small-molecule inhibitor for HR+/HER2- metastatic breast cancer, representing a potential first-in-class program.
Quantifiable outcome
- Compressed drug discovery timeline from 6 years to under 2 years
- +2 more outcomes
Companies that use Iambic
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles1 record
Iambic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
Iambic partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and secondary.
- BayercoreSourcing partnership leveraging Iambic's AI-powered Enchant and NeuralPLexer platforms for small molecule drug discovery and development. Collaboration aims to identify new drug pathways, accelerate optimization timelines, and improve decision-making across Bayer's R&D value chain.
- Takeda PharmaceuticalscoreMulti-year collaboration to advance AI-driven design of small molecules for oncology and gastrointestinal/inflammation therapeutic areas. Iambic will receive upfront payments, research funding, technology access fees, and success-based milestone payments potentially exceeding $1.7 billion, plus royalties on net sales of any products developed.
- Jazz PharmaceuticalssecondaryResearch collaboration evaluating IAM1363 (HER2 inhibitor) and zanidatamab combination for HER2-positive breast cancer patients previously treated with trastuzumab deruxtecan.
- Revolution MedicinessecondaryTechnology and research collaboration using Iambic's AI discovery tools (NeuralPLexer) to pursue new drug candidates. Revolution Medicines gained access to Iambic's platform for target prediction.
- LundbecksecondaryAI drug discovery collaboration focused on treatments for migraine. Part of Lundbeck's strategy to integrate AI across its drug discovery operations.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Iambic competitors and assessment
Company assessmentDirect peers
- Exscientia: Pioneer in AI-driven small-molecule drug design with multiple pharma partnerships (Bayer, Sanofi, GSK). Directly comparable technology focus (small-molecule AI design) and partnership GTM.
- Atomwise: AI-driven small-molecule discovery platform with multi-pharma partnerships. Comparable technology approach (structure-based ML) and licensing/collaboration business model.
- Schrödinger, Inc. Physics-based computational chemistry and ML platform for drug discovery, with both internal pipeline and pharma software licensing. Comparable platform-plus-pipeline model.
- Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company combining high-throughput biology with ML. Most directly comparable to Iambic in combining proprietary AI platforms with integrated wet-lab automation and pharma partnerships (e.g., Roche/Genentech, Bayer).
- Genesis Therapeutics: AI-native biotech combining foundation models and physics-based methods for small-molecule discovery. Closely comparable platform architecture to Iambic's NeuralPLexer/Enchant approach.
- Insitro: AI-driven drug discovery company using ML on proprietary high-throughput biological data. Targets similar pharma partnership business model and competes for the same enterprise pharma customer base.
- BenevolentAI: AI drug discovery company using ML on biomedical knowledge graphs to identify targets and drug candidates. Comparable AI-discovery-to-clinical-pipeline model.
- XtalPi: AI + robotics-driven drug discovery company with extensive pharma partnerships. Comparable combination of predictive AI and automated experimentation to accelerate small-molecule discovery.
- Isomorphic Labs: Alphabet-owned AI drug discovery company spun out of DeepMind. Competes head-to-head for pharma AI partnerships and uses similar transformer and protein-structure-prediction approaches (AlphaFold lineage).
Broad incumbents
- NVIDIA BioNeMo / Clara Discovery: While NVIDIA is a tech incumbent and a Iambic investor, its BioNeMo/Clara platform provides AI drug-discovery foundation models and infrastructure that increasingly compete with or commoditize platform-layer offerings like Enchant/NeuralPLexer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Iambic social profiles
Digital presenceIambic financial estimates
Financial estimateRevenue estimate
Valuation estimate
Iambic leadership team
Management profileNumber of profiles
Profiles7 records
Iambic funding detail
Funding detailFunding overview
Funding rounds5 records
Investors25 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Iambic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Iambic
What does Iambic do?
Iambic Therapeutics is a clinical-stage biotechnology company that develops an AI-driven drug discovery platform combining proprietary transformer models (Enchant) and protein-ligand structure prediction (NeuralPLexer) with automated high-throughput wet-lab experimentation. The company advances an internal pipeline of differentiated small-molecule oncology candidates (IAM1363, IAM-K1, IAM-C1) and licenses its AI platform to large pharmaceutical companies through multi-year collaboration agreements.
Is Iambic a public or private company?
Iambic is a private company. It is classified as venture growth investor backed and is currently operating.
When was Iambic founded?
Iambic was founded in 2020. It employs 101 to 250 people.
Where is Iambic based?
Iambic is headquartered in San Diego, United States, in the North America region.
How does Iambic make money?
Three revenue lines are on record. Partnership Milestone Payments are the primary driver. The others are technology Platform Licensing and royalty Payments.
Who are Iambic's main competitors?
Direct peers on record are Exscientia, Atomwise, Schrödinger, Inc., Recursion Pharmaceuticals, Genesis Therapeutics, Insitro, BenevolentAI, XtalPi and Isomorphic Labs. NVIDIA BioNeMo / Clara Discovery is listed as a broad incumbent.
Does Iambic have an API?
No public API is recorded for Iambic.
What industry is Iambic in?
Iambic's product category is AI-driven drug discovery platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.